Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
Akero Therapeutics (AKRO) announced results from new analyses of the 96-week Phase 2b HARMONY trial of efruxifermin, EFX, in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, MASH, in an oral presentation and a poster presentation at the European Association for the Study of the Liver, EASL, Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. The presentations corroborate the antifibrotic activity previously reported by conventional pathology for EFX in patients with pre-cirrhotic MASH. Specifically, among patients treated with EFX, digital pathology analysis by HistoIndex's AI-based qFibrosis showed concordance at the individual level with two non-invasive tests of liver fibrosis-ELF test score and liver stiffness measurement-with more than half of patients treated with 50mg EFX classified as responders by all three endpoints compared to fewer than 5% of placebo patients.
Protect Your Portfolio Against Market Uncertainty
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 days ago
- Yahoo
Objective launches purpose-built planning platform at PIA Congress 2025
Objective Build, now ready for Australian councils, is announced Capitalises on the Objective Build success in New Zealand Designed for Aussie planners from the ground up to help tackle the housing crisis DARWIN, Australia, May 29, 2025 /PRNewswire/ -- Objective Corporation (ASX: OCL) today officially announced Objective Build, a transformative planning and development approvals platform designed specifically for local government in Australia. The announcement was made live from the Planning Institute of Australia (PIA) Congress 2025 in Darwin, where Objective is appearing as Platinum Sponsor. Regionalised for Australian councils, Objective Build is already generating strong interest among planners, CIOs, and local government leaders attending the event. "The feedback we've had this morning has been exceptional," said Andrea Breen, VP of Local Government Solutions at Objective. "Planners are excited to see a platform that finally reflects the realities of their day-to-day work—fast, fit-for-purpose, and designed with them at the centre." Built for Planning, Not Repurposed for It Objective Build replaces fragmented systems, spreadsheets, and retrofitted ERPs with a purpose-built platform that simplifies development assessment, accelerates approvals, and restores confidence in the process—for councils, applicants, and communities. Key features include: Smart workflow automation for faster approvals and fewer delays. AI-powered context to surface relevant past decisions and increase consistency. End-to-end compliance visibility with integration to the NSW Planning Portal. Real-time dashboards for team leaders and executives. "Planning teams across Australia are under pressure to do more with less," said Breen. "Objective Build helps planners shift their focus from repetitive admin to real planning—making confident, high-quality decisions that shape stronger communities." AI That Assists, Not Replaces At the heart of Objective Build is council-ready AI that enhances human judgment. The platform supports planners by generating letters, summarising submissions, and surfacing similar DAs—all while leaving every final decision in the hands of a qualified professional. "It's not about automating decisions—it's about empowering planners," said Breen. "Objective Build acts like a digital planning assistant, not a replacement." Built for Australian Councils—With Local Nuance, National Impact Objective Build isn't just another software solution—it's a planning transformation platform created specifically for local government in Australia. Councils today are being asked to do more with less: Approve more housing, faster. Stay compliant with changing regulations. Earn back trust from increasingly frustrated communities. Attract and retain skilled planners in a competitive market. But many councils are still relying on repurposed ERP systems, spreadsheets, and ageing bespoke tools that come up short as they were never designed for planning in the first place. Objective Build changes that. Built with and for Australian planning teams. Ready-to-deploy modules for NSW, with configurations underway for Victoria, Queensland, and other states. Seamlessly integrates with finance systems, records management, and the NSW Planning Portal. Backed by Objective's deep experience supporting 220+ Australian councils and public sector organisations around the world for over 30 years. "You don't need a large IT team or big transformation budget to get started," said Breen. "We've built Objective Build to be ready, out of the box—with flexibility for your council's specific processes, and support that understands how local government really works." Whether you're a CIO, a GM, or a Director of Planning wondering how to future-proof your teams, Objective Build is the modern platform that meets you where you are—and grows with you. Learn more about Objective Build. About Objective Corporation Objective (ASX: OCL) helps government and regulated industries deliver better services to their communities. From digital planning to secure content management and regulation, Objective's software is trusted by councils, agencies, and regulators across Australia, New Zealand, and the UK. View original content to download multimedia: SOURCE Objective Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Yahoo
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., Ltd. ("Eisai"), and Lenvatinib mesylate ("lenvatinib") (*2) will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. The abstract of the study has been released today. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797(*3)), expansion cohort of advanced endometrial cancer patients progressed following platinum-based chemotherapy and anti-PD-(L)1 immunotherapy have been implemented by Eisai and the enrollment of 30 patients was completed. By data cutoff (Oct 22, 2024), with 9 patients remaining on treatment, 30% (9 patients) showed the confirmed response (decrease of tumor size > 30%) for an overall response rate of 30.0%. Furthermore, among patients without prior Lenvatinib treatment, the overall response rate was 42.9%. Completing the enrollment of dose expansion cohort (n=30), the results confirmed promising preliminary antitumor activity of E7386 + Lenvatinib with a manageable safety profile. For the subsequent dose-optimization part for E7386 + LEN in advanced endometrial cancer, enrollment of patients had been initiated (NCT04008797). (*1) E7386 E7386 is an orally available small molecule CBP/ β-catenin inhibitor that inhibits protein-protein interactions between the transcription factor CBP and β-catenin, and regulates the Wnt signaling. E7386 achieved clinical POC (Proof of concept) in October 2021 and following clinical studies are ongoing including phase I for solid tumors as monotherapy, Phase Ib for solid tumors in combination with tyrosine kinase inhibitor Lenvatinib, Phase Ib/II for solid tumors in combination with pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA. (*2) Lenvatinib Lenvatinib is a multi-kinase inhibitor, discovered by Eisai and being co-developed and co-commercialized under a collaboration agreement with Merck & Co., Inc., Rahway, NJ, USA, which inhibits vascular endothelial growth factor receptors (VEGFRs),VEGFR1, VEGR2, VEGFR3 and fibroblast growth factor receptors (FGFRs), FGFR1, FGFR2, FGFR3, FGFR4, and other receptor tyrosine kinases, PDGFR-alpha, KIT, RET. Lenvatinib have been approved for thyroid cancer, hepatocellular carcinoma, thymic caner and renal cell carcinoma (in combination with Everolimus or pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA.). Lenvatinib is also approved for endometrium cancer in combination with pembrolizumab (*3) NCT04008797 NCT04008797 is an open-label Phase Ib study of E7386 in combination with other anticancer drug, Lenvatinib for the patients with solid tumors. The study has been implemented by Eisai in Japan, Korea, Taiwan region, US, and France determine the safety and the recommended phase 2 dose (RP2D) and also to see the pharmacokinetics and efficacy of E7386 + Lenvatinib. Enrolment of each cohort of hepatic, colon, endometrial cancers are ongoing. About PRISM BioLab PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics. PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively. View original content to download multimedia: SOURCE PRISM BioLab Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Yahoo
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other stocks that skyrocketed today. Ten companies boasted whopping gains on Tuesday despite a wider market pessimism, as a flurry of corporate developments, including impressive earnings and bullish outlooks, sparked buying appetite. In contrast, Wall Street's main indices all finished in the red territory. The Dow Jones was down by 0.27 percent, the S&P 500 dropped 0.39 percent, and the tech-heavy Nasdaq declined 0.38 percent. In this article, we named the 10 best-performing stocks during the trading session and detailed the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A scientist in a lab coat examining a sample under a microscope in a laboratory. Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news that it was exploring a sale. According to a report by StreetInsider, Akero Therapeutics, Inc. (NASDAQ:AKRO) is now in talks with an investment bank to assist with the process. However, it added that the company's early interest and strategic review might not necessarily translate to a sale. In its latest earnings release, Akero Therapeutics, Inc. (NASDAQ:AKRO) widened its net loss by 32.6 percent to $70.7 million from $53.3 million in the same period last year. Operating expenses surged by 34.9 percent to $80.88 million from $59.95 million year-on-year. Net loss per common share was at 90 cents, similar to the same period a year ago. Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Overall, AKRO ranks 10th on our list of today's best-performing stocks. While we acknowledge the potential of AKRO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AKRO and that has 100x upside potential, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
